#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	19508	16S	1529	1529	99.87	16S.l15.c4.ctg.1	2409	996.6	0	.	n	.	0	A69G	SNP	69	69	A	464	464	G	1199	G,A,T,C	876,319,1,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	19508	16S	1529	1529	99.87	16S.l15.c4.ctg.1	2409	996.6	0	.	n	.	0	C1450T	SNP	1450	1450	C	1845	1845	T	1267	T,G,C,A	1261,3,2,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	19508	16S	1529	1529	99.87	16S.l15.c4.ctg.1	2409	996.6	1	SNP	n	C1184T	0	.	.	1184	1184	C	1579	1579	C	1263	C	1263	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	33348	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3963	1048.8	0	.	n	.	0	G1337A	SNP	1337	1337	G	1909	1909	A	1413	A,C	1412,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	33348	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3963	1048.8	0	.	n	.	0	T1971C	SNP	1971	1971	T	2543	2543	C	1160	C,T,A	1157,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	33348	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3963	1048.8	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	3169	3169	T	1195	T,C,A	899,295,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	33348	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3963	1048.8	1	SNP	n	A2045G	0	.	.	2045	2045	A	2617	2617	A	1029	A,G	1028,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_M_01364c	folP.WHO_M_01364c	1	1	539	2804	folP	852	852	99.88	folP.l6.c4.ctg.1	1912	182.8	0	.	p	.	0	E151K	NONSYN	451	453	GAA	1011	1013	AAA	254;256;257	A,C;A,C;A,C	253,1;255,1;254,3	.	.
folP.WHO_M_01364c	folP.WHO_M_01364c	1	1	539	2804	folP	852	852	99.88	folP.l6.c4.ctg.1	1912	182.8	1	SNP	p	R228S	1	.	.	682	684	AGC	1242	1244	AGC	261;259;258	A;G;C	261;259;258	folP.WHO_M_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	7392	gyrA	2751	2751	100.0	gyrA.l6.c4.ctg.1	3747	246.1	1	SNP	p	S91F	0	.	.	271	273	TCC	764	766	TCC	276;274;272	T,G,A;C;C,A	274,1,1;274;271,1	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	7392	gyrA	2751	2751	100.0	gyrA.l6.c4.ctg.1	3747	246.1	1	SNP	p	D95G	0	.	.	283	285	GAC	776	778	GAC	275;274;273	G;A,G;C	275;273,1;273	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	7392	gyrA	2751	2751	100.0	gyrA.l6.c4.ctg.1	3747	246.1	1	SNP	p	D95N	0	.	.	283	285	GAC	776	778	GAC	275;274;273	G;A,G;C	275;273,1;273	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	27	2580	mtrR	633	633	100.0	mtrR.l15.c17.ctg.1	1685	190.4	1	SNP	p	G45D	0	.	.	133	135	GGC	640	642	GGC	278;281;285	G;G;C,G	278;281;284,1	mtrR.WHO_X_01389:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	1492	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1532	121.1	0	.	n	.	0	A197.	DEL	197	197	A	908	908	A	315	A	314	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	6922	parC	2304	2304	99.91	parC.l6.c17.ctg.1	3358	257.0	1	SNP	p	D86N	0	.	.	256	258	GAC	767	769	GAC	325;329;327	G;A,G,C;C	325;327,1,1;327	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	6922	parC	2304	2304	99.91	parC.l6.c17.ctg.1	3358	257.0	1	SNP	p	S87R	0	.	.	259	261	AGT	770	772	AGT	329;331;332	A;G;T,G	329;331;331,1	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	6922	parC	2304	2304	99.91	parC.l6.c17.ctg.1	3358	257.0	1	SNP	p	S87I	0	.	.	259	261	AGT	770	772	AGT	329;331;332	A;G;T,G	329;331;331,1	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	6922	parC	2304	2304	99.91	parC.l6.c17.ctg.1	3358	257.0	1	SNP	p	S87W	0	.	.	259	261	AGT	770	772	AGT	329;331;332	A;G;T,G	329;331;331,1	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	6922	parC	2304	2304	99.91	parC.l6.c17.ctg.1	3358	257.0	1	SNP	p	S88P	0	.	.	262	264	TCC	773	775	TCC	336;337;335	T,C;C,A;C,T	335,1;335,2;334,1	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	5550	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3283	211.0	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1830	1832	GGC	293;291;292	G,T;G,T;C,A	291,2;289,2;291,1	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.9.001	penA.9.001	1	1	539	5444	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2663	253.9	0	.	p	.	0	A456E	NONSYN	1366	1368	GCG	1821	1823	GAG	288;287;291	G;A,C;G	288;285,2;291	.	.
penA.9.001	penA.9.001	1	1	539	5444	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2663	253.9	1	SNP	p	A311V	0	.	.	931	933	GCA	1386	1388	GCA	296;301;302	G,T;C;A	295,1;301;302	penA.9.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	539	5444	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2663	253.9	1	SNP	p	I312M	0	.	.	934	936	ATC	1389	1391	ATC	299;305;306	A,C;T,C;C	298,1;304,1;306	penA.9.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	539	5444	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2663	253.9	1	SNP	p	V316T	0	.	.	946	948	GTG	1401	1403	GTG	310;312;316	G;T;G	310;312;316	penA.9.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	539	5444	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2663	253.9	1	SNP	p	V316P	0	.	.	946	948	GTG	1401	1403	GTG	310;312;316	G;T;G	310;312;316	penA.9.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	539	5444	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2663	253.9	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1905	1907	ACC	340;342;340	A,C;C,G;C	338,2;341,1;340	penA.9.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	539	5444	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2663	253.9	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1959	1961	GCG	315;320;317	G;C,G;G	315;319,1;317	penA.9.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	539	5444	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2663	253.9	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1959	1961	GCG	315;320;317	G;C,G;G	315;319,1;317	penA.9.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	539	5444	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2663	253.9	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2082	2084	GGC	329;325;322	G;G,A;C	329;323,2;322	penA.9.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	539	5444	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2663	253.9	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2091	2093	GGC	328;327;329	G,A;G;C	327,1;327;329	penA.9.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	539	5444	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2663	253.9	1	SNP	p	L552S	0	.	.	1654	1656	CTG	2109	2111	CTG	318;319;320	C;T,G;G	318;318,1;320	penA.9.001:1:1:L552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	7518	ponA	2397	2397	100.0	ponA.l6.c4.ctg.1	3513	267.1	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1836	1838	CCG	335;336;339	C,G;C,T;G,C	333,2;335,1;338,1	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	3374	porA	1146	1146	99.65	porA.l15.c4.ctg.1	2207	190.7	0	.	p	.	0	M83fs	FSHIFT	247	247	A	735	735	C	261	C,A	260,1	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	414	porB1a	984	104	94.23	porB1a.l15.c4.ctg.4	185	65.5	0	.	p	.	0	M18T	NONSYN	52	54	ATG	133	135	ACG	83;79;74	A;C;G	83;79;74	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	414	porB1a	984	104	94.23	porB1a.l15.c4.ctg.4	185	65.5	0	.	p	.	0	E32Q	NONSYN	94	96	GAA	175	177	CAA	20;19;17	C;A;A,C	20;19;16,1	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	414	porB1a	984	104	94.23	porB1a.l15.c4.ctg.4	185	65.5	0	.	p	.	0	S34Y	NONSYN	100	102	TCC	181	183	TAC	6;2;1	T;A;C	6;2;1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3932	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	1561	308.5	0	.	p	.	0	N38E	NONSYN	112	114	AAT	456	458	GAA	348;341;342	G,T,A;A,C;A	346,1,1;340,1;342	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3932	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	1561	308.5	0	.	p	.	0	N134D	NONSYN	400	402	AAT	744	746	GAT	333;331;332	G;A;T	333;331;332	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3932	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	1561	308.5	0	.	p	.	0	P175S	NONSYN	523	525	CCA	867	869	TCA	324;324;326	T,G,A;C;A	322,1,1;324;326	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3932	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	1561	308.5	0	.	p	.	0	A218V	NONSYN	652	654	GCC	996	998	GTC	344;338;334	G;T,G;C,T,A	344;337,1;332,1,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3932	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	1561	308.5	0	.	p	.	0	S292T	NONSYN	874	876	TCT	1218	1220	ACT	336;337;335	A,T;C;T,A	335,1;337;334,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3932	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	1561	308.5	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1326	1328	GCA	326;326;327	G;C;A,T	326;326;326,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3932	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	1561	308.5	1	SNP	p	G120K	1	.	.	358	360	AAG	702	704	AAG	346;341;342	A,C;A;G,C,A	345,1;341;340,1,1	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3932	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	1561	308.5	1	SNP	p	D121N	0	.	.	361	363	GAC	705	707	GAC	341;342;342	G,C;A;C,G	340,1;342;340,2	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3932	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	1561	308.5	1	SNP	p	A121D	1	.	.	361	363	GAC	705	707	GAC	341;342;342	G,C;A;C,G	340,1;342;340,2	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	539	13084	rpoB	4179	4179	99.95	rpoB.l15.c4.ctg.1	5349	304.9	0	.	p	.	0	T30A	NONSYN	88	90	ACC	619	621	GCC	297;299;299	G;C;C,A	297;299;298,1	.	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	539	13084	rpoB	4179	4179	99.95	rpoB.l15.c4.ctg.1	5349	304.9	1	SNP	p	H553N	1	H553N	NONSYN	1657	1659	CAT	2188	2190	AAT	360;358;359	A;A,C;T,G,C,A	360;357,1;356,1,1,1	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1982	rpsJ	312	312	100.0	rpsJ.l15.c17.ctg.1	1344	182.9	1	SNP	p	V57M	1	.	.	169	171	ATG	743	745	ATG	344;342;342	A;T,A;G	344;341,1;342	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
